Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

• Published in: Kidney international Vol. 96; no. 4; pp. 995 - 1004
• Main Authors: Cavero, Teresa, Arjona, Emilia, Soto, Karina, Caravaca-Fontán, Fernando, Rabasco, Cristina, Bravo, Luis, de la Cerda, Francisco, Martín, Nadia, Blasco, Miquel, Ávila, Ana, Huerta, Ana, Cabello, Virginia, Jarque, Ana, Alcázar, Concepción, Fulladosa, Xavier, Carbayo, Javier, Anaya, Sara, Cobelo, Carmen, Ramos, Natalia, Iglesias, Elena, Baltar, José, Martínez-Gallardo, Rocío, Pérez, Lourdes, Morales, Enrique, González, Roberto, Macía, Manuel, Draibe, Juliana, Pallardó, Luis, Quintana, Luis F., Espinosa, Mario, Barros, Xoana, Pereira, Fernando, Cao, Mercedes, Moreno, Juan Antonio, Rodríguez de Córdoba, Santiago, Praga, Manuel
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2019
• Subjects: atypical hemolytic uremic syndrome; complement; eculizumab; malignant hypertension; atypical hemolytic uremic syndrome; malignant hypertension; eculizumab; complement
• ISSN: 0085-2538; 1523-1755
• DOI: 10.1016/j.kint.2019.05.014

Malignant hypertension is listed among the causes of secondary thrombotic microangiopathy, but pathogenic mutations in complement genes have been reported in patients with hypertension-induced thrombotic microangiopathy. Here we investigated the frequency and severity of hypertension in 55 patients with primary atypical hemolytic uremic syndrome (aHUS). A genetic analysis was performed in all patients, and funduscopic examination was performed in all the patients with Grades 2 and 3 hypertension. A cohort of 110 patients with malignant hypertension caused by diseases other than aHUS served as control. Thirty-six patients with aHUS presented Grade 2 or Grade 3 hypertension and funduscopic examination showed malignant hypertension in 19. Genetic abnormalities in complement were found in 19 patients (37% among patients with malignant hypertension). Plasmapheresis was performed in 46 patients and 26 received eculizumab. Renal and hematological responses were significantly lower after plasmapheresis (24%) than after eculizumab (81%). Renal survival was significantly higher in patients treated with eculizumab (85% at one, three and five years) compared to patients who did not receive this treatment (54%, 46% and 41%), respectively. Response to eculizumab was independent of hypertension severity and the presence of complement genetic abnormalities. Among patients with malignant hypertension caused by other diseases the prevalence of thrombotic microangiopathy was very low (5%). Thus, severe and malignant hypertension are common among patients with aHUS and eculizumab treatment leads to a higher renal survival when compared to plasmapheresis. However, thrombotic microangiopathy is uncommon among patients presenting with malignant hypertension caused by diseases other than aHUS. [Display omitted]